Iontophoretic drug delivery system

• US 6,745,071 B1
• Filed: 02/21/2003
• Issued: 06/01/2004
• Est. Priority Date: 02/21/2003
• Status: Expired due to Term

• Current Assignee: Teva Pharmaceuticals International GmbH (Teva Pharmaceutical Industries Limited)
• Original Assignee: Birch Point Medical, Inc.
• Inventors: Anderson, Carter R., Morris, Russell L., Anderson, Clayton J., Grace, Lori A.
• Primary Examiner(s): Casler, Brian L.
• Assistant Examiner(s): RODRIGUEZ, CRIS LOIREN
• Application Number:
  US10/371,851
• Time in Patent Office: 466 Days
• Field of Search: 604/20, 604/115, 604/501, 607/153, 607/148, 607/149, 607/151, 607/152
• US Class Current: 604/20
• CPC Class Codes: A61N 1/30 Apparatus for iontophoresis, i.e. transfer of media in ionic state by an electromotoric force into the body, or cataphoresis

Abstract

A reliable, self-contained iontophoretic drug delivery system is disclosed which enjoys a long stable shelf life and which is easy for the user to activate and employ. This system includes a wearable iontophoretic device that is prepackaged as a complete self-contained unit which includes the active species or drug to be administered and counter ions. The system includes a provision for isolating moisture sources from the electrodes and from the power source during storage and provides a simple, user-friendly mechanism to connect the drug to be administered and counter ion reservoirs to the electrodes and the device to the skin of a user in order to activate the device circuit. All elements of the device are contained in a single outer package.

Claims

1. A self-contained, wearable, pre-packaged iontophoretic drug delivery system comprising:

(a) a removable substrate;

(b) an aqueous anode matrix removably carried on said substrate and isolated by a water impermeable release membrane;

(c) an aqueous cathode matrix removably carried on said substrate and isolated by a water impermeable release membrane;

(d) an iontophoresis device including an anode electrode and a cathode electrode and a source of electric power carried on said substrate;

(e) wherein said iontophoresis device includes shaped recesses associated with said anode and said cathode configured to receive said aqueous anode matrix and said aqueous cathode matrix, respectively, in conductive relation;

(f) at least one fold line on said removable substrate to enable the pre-packaged system to fold on itself to thereby associate said anode matrix and said cathode matrix with said anode electrode and said cathode electrode; and

(g) an amount of a therapeutic ion species to be delivered transdermally by iontophoresis located in at least one of said anode matrix, said cathode matrix and said iontophoresis device.

2. An iontophoretic drug delivery system as in claim 1 further comprising an amount of adhesive to retain said aqueous anode matrix and said aqueous cathode matrix initially on said substrate.

3. An iontophoretic drug delivery system as in claim 1 wherein said water impermeable release membrane associated with said aqueous anode matrix is separate from said water impermeable release membrane associated with said aqueous cathode matrix and wherein both said water impermeable release membranes are provided with pull-tabs enabling them to be peeled off when desired.

4. An iontophoretic drug delivery system as in claim 1 wherein removal of said removable substrate exposes said anode matrix and said cathode matrix for application to the skin of a patient.

5. An iontophoretic drug delivery system as in claim 1 wherein said aqueous anode matrix and said aqueous cathode matrix are carried in recesses in said substrate.

6. An iontophoretic drug delivery system as in claim 1 wherein said substrate is provided with a plurality of fold lines.

7. An iontophoretic drug delivery system as in claim 1 wherein said therapeutic ion species is a form of fentanyl and is located in said anode matrix.

8. An iontophoretic drug delivery system as in claim 1 wherein said anode matrix and said cathode matrix include a hydrogel or highly viscous material.

9. An iontophoretic drug delivery system as in claim 8 wherein said hydrogel or highly viscous material is selected from the group consisting of agarose, polyvinyl alcohol, polyvinylpyrrolidone, methyl cellulose, hydroxypropyl methylcellulose and, carboxymethyl cellulose, and combinations thereof.

10. An iontophoretic drug delivery system as in claim 1 wherein said anode matrix and said cathode matrix include a fibrous material.

11. An iontophoretic drug delivery system as in claim 10 wherein said fibrous material is selected from the group consisting of cellulose, polyester and polypropylene and combinations thereof.

12. An iontophoretic drug delivery system as in claim 10 wherein said anode matrix and said cathode matrix include a hydrogel or highly viscous material.

13. An iontophoretic drug delivery system as in claim 11 wherein said anode matrix and said cathode matrix contain a hydrogel material or highly viscous material selected from the group consisting of agarose, polyvinyl alcohol, polyvinylpyrrolidone, methyl cellulose, hydroxypropyl methylcellulose, carboxymethyl cellulose are also acceptable.

14. An iontophoretic drug delivery system as in claim 1 wherein said amount of therapeutic ion species to be delivered transdermally by iontophoresis is located in said iontophoresis device in a dry state prior to activation.

15. An iontophoretic drug delivery system as in claim 1 wherein said anode matrix and said cathode matrix include at least one additive selected from the group consisting of humectants and antifungel agents.

16. An iontophoretic drug delivery system as in claim 1 wherein said iontophoresis device includes a voltage control system.

17. An iontophoretic drug delivery system as in claim 16 wherein said voltage control device further includes a two-position, high-low switch.